Business
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated approval pathway mid-2026 WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71%, with 11.9 µM total AAT in the 200 mg biweekly cohort; effects were consistent with 400 mg monthly dosing regi
About this update from Wave Life Sciences Ltd.
[{"type":"image","alt":"Wave Life Sciences USA, Inc.","displaySize":"","headline":null,"caption":"Wave Life Sciences USA, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QJMfSvqBwjn8wHv3A.LL3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNQ--/https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6","width":300,"height":161},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/QJMfSvqBwjn8wHv3A.LL3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNQ--/https://media.zenfs.com/en/globenewswire.com/fadcc4b7b9a8938be97ac36a2e160ac6","width":300,"height":161}},"lazy":false},{"type":"text","content":"Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing ","length":212,"tagName":"p"},{"type":"text","content":"On track for feedback from FDA on potential accelerated approval pathway mid-2026","length":81,"tagName":"p"},{"type":"text","content":"WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71%, with 11.9 µM total AAT in the 200 mg biweekly cohort; effects were consistent with 400 mg monthly dosing regimen, with 13.6 µM total AAT; editing was sustained at least three months following last dose","length":297,"tagName":"p"},{"type":"text","content":"Restored dynamic AAT production with two new observations of elevated AAT during acute phase responses following mild upper respiratory infections, building on prior observation of 20.6 µM of total AAT during an acute phase response two weeks post-single 200 mg dose","length":266,"tagName":"p"},{"type":"text","content":"RNA editing offers distinct safety advantages (reversible, no bystander edits or off-target edits) over DNA editing; WVE-006 continues to be generally safe and well tolerated with no liver toxicities","length":199,"tagName":"p"},{"type":"text","content":"Wave to host investor webcast at 5:30 p.m. ET today ","length":51,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broa...